The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis
Authors' conclusion
The utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively.
Study context
- Population
- Patients who underwent hip arthroplasty for femoral neck fractures (femoral neck fracture (FNF))
- Comparison
- Osteoporosis medications vs no osteoporosis treatment for PPF prevention
- Outcome
- Break-even ARR in PPF rate at which osteoporosis treatment is economically justified
- Follow-up
- 3 years
Methodological detailssensitivity analyses
- Sensitivity analyses
Main finding
As reported in the abstract
Break-even PPF prevention with oral bisphosphonates
Oral bisphosphonates economically justified if preventing one out of 56 PPFs (absolute risk reduction (ARR))
1.8%
Estrogen hormonal therapy economically viable if reducing PPF rate by
1.5%
Overall treatment economically viable for PPF prophylaxis only if 3-year costs of agents are less than
$1500
Original publication
The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis. Osteoporos Int. Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →